A new gene editing tool that helps cellular machinery skip parts of genes responsible for diseases has been applied to reduce the formation of amyloid-beta plaque precursors in a mouse model of ...
Both antibodies target pyroglutamate-amyloid-beta. Eli Lilly’s Kisunla targets a pyroglutamate form of amyloid beta, as does the candidate at the heart of AbbVie’s $1.4 billion takeover of ...